This isn’t the first time AngioDynamics shares have seen an “it’s different this time” rally, and the question remains whether management can execute on these promising new product opportunities and drive something more than the low single-digit revenue growth and single-digit FCF margins that have been the company’s lot for more than a decade. The shares have doubled since then, as management has done a good job of getting the story out there on the company’s three new growth drivers – AngioVac, Auryon, and NanoKnife. Writing about AngioDynamics ( NASDAQ: ANGO) a little more than six months ago, I said that rebuilding investor confidence in the prospect of sustainable mid-single-digit revenue growth (or better) could take the shares into the high teens or higher. © Copyright of Globes Publisher Itonut (1983) Ltd.Photo by VIKTORIYA KABANOVA/iStock via Getty Images Published by Globes, Israel business news - en.il - on October 3, 2019 Oppenheimer served as the investment banker of Eximo Medical for this deal. Throughout acquisitions by foreign medical device corporations, innovation centers are being built in Israel, centers that beyond the construction of an R&D activity in the forefront of the medical technology in Israel, allows a fast time to market, to the benefit of the patients." As part of the acquisition, Eximo will continue to operate in Israel, which is a growing phenomenon. Irit Yaniv said, "By acquiring Eximo and its technology, AngioDynamics is enters a growing market of over $500 million a year (and potentially with billions of dollars a year after completion of development of more indications), with a breakthrough medical solution that offers greater versatility, wider treatment range and clinical data proving its efficacy. RELATED ARTICLESĬatheter developer Eximo Medical raises $1.6mĮximo Medical chairman and Accelmed partner Dr. In addition to reducing the risk of embolization to the patient, the B-Laser technology offers caregivers and patients tissue selectivity and is indicated to provide treatment for In Stent Restenosis (ISR). We would also like to thank the number of physicians that have already partnered with us during our journey, and we look forward to continuing our work together as we expand our physician base."ĭifferentiated from other legacy medical devices, Eximo’s B-Laser technology is the only system capable of delivering short, high-power pulsed laser energy in 355nm wavelength through the optical fibers in the catheter (a process that was considered impossible in the past) without compromising the integrity of the catheter during atherectomy procedures. Eximo’s B-Laser™ represents a technological breakthrough among medical devices used in atherectomy procedures to treat PAD today.Įximo Medical CEO Yoel Zabar said, "We believe that AngioDynamics’ existing resources and commercial acumen will enable a large number of patients to benefit from Eximo’s laser technology, and we look forward to extending its utility into other indications within vascular and elsewhere. The market is ripe for disruption and the safety, precision technology, and efficiency offered by the B-Laser technology gives physicians a substantially differentiated alternative to legacy atherectomy devices while offering patients a much safer procedure "Ĭaregivers provide atherectomy treatment to over 200,000 Americans annually. Additional investors other than Accelmed, Arkin Holdings and Peregrine Ventures, include Tal Capital, Rami Lipman, AMIT and the Technion.ĪngioDynamics president and CEO Jim Clemmer said, The acquisition of Eximo brings a remarkable, foundational technology to our portfolio that will change the way that caregivers deliver treatment to treat people with PAD. Uri Geiger, in cooperation with Incentive incubator managed by Lior Shahori (the incubator is owned by Peregrine Ventures and supported by the Innovation Authority), the entrepreneur Ilan Ben Oren who serves also as Accelmed CTO, Dr. Eximo Medical was founded in 2012 by Accelmed fund managed by Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |